KD Logo

Aurinia Pharmaceuticals Inc [AUPH] stock was sold by Bailey Jeffrey Allen at the price of US$38416.0

In a filing, Aurinia Pharmaceuticals Inc revealed its Director Bailey Jeffrey Allen unloaded Company’s shares for reported $38416.0 on Nov 11 ’24. In the deal valued at $8.43 per share,4,557 shares were sold. As a result of this transaction, Bailey Jeffrey Allen now holds 13,356 shares worth roughly $0.11 million.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

Then, Smith Karen L. sold 5,241 shares, generating $44,182 in total proceeds. Upon selling the shares at $8.43, the Director now owns 12,672 shares.

Before that, Habig Scott Michael sold 18,249 shares. Aurinia Pharmaceuticals Inc shares valued at $96,902 were divested by the Chief Commercial Officer at a price of $5.31 per share. As a result of the transaction, Habig Scott Michael now holds 456,338 shares, worth roughly $3.71 million.

Oppenheimer downgraded its Aurinia Pharmaceuticals Inc [AUPH] rating to a Perform from a an Outperform in a research note published on Oppenheimer also remained covering AUPH and has increased its forecast on December 10, 2021 with a “an Outperform” recommendation from previously “Perform” rating. Oppenheimer revised its rating on October 28, 2021. It rated AUPH as “a Perform” which previously was an “an Outperform”.

Price Performance Review of AUPH

On Tuesday, Aurinia Pharmaceuticals Inc [NASDAQ:AUPH] saw its stock jump 1.50% to $8.13. Over the last five days, the stock has lost -2.98%. Aurinia Pharmaceuticals Inc shares have fallen nearly -9.57% since the year began. Nevertheless, the stocks have fallen -5.47% over the past one year. While a 52-week high of $10.05 was reached on 01/10/24, a 52-week low of $4.71 was recorded on 04/18/24. SMA at 50 days reached $7.32, while 200 days put it at $6.08.

Levels Of Support And Resistance For AUPH Stock

The 24-hour chart illustrates a support level at 7.97, which if violated will result in even more drops to 7.80. On the upside, there is a resistance level at 8.22. A further resistance level may holdings at 8.30. The Relative Strength Index (RSI) on the 14-day chart is 61.70, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.16, which suggests price will go down in the next trading period. Percent R suggests that price movement has been low at 35.67%. Stochastics %K at 61.79% indicates the stock is a holding.

How much short interest is there in Aurinia Pharmaceuticals Inc?

A steep rise in short interest was recorded in Aurinia Pharmaceuticals Inc stocks on 2024-10-31, growing by 0.11 million shares to a total of 7.34 million shares. Yahoo Finance data shows the prior-month short interest on 2024-09-30 was 7.24 million shares. There was a rise of 1.45%, which implies that there is a positive sentiment for the stock.

The most recent change occurred on January 25, 2021 when H.C. Wainwright resumed its ‘”a Buy”‘ rating for the stock and retained the price target to $35.

Most Popular